

Agenda

Experience Exchange between United Kingdom and Sweden on Lung Cancer Screening

To improve early cancer diagnosis, outcomes and care for patients, Sweden is looking into the potential of introducing a national screening program for lung cancer. The purpose of this meeting is to learn from experiences of lung cancer screening studies and the conclusions drawn so far in the UK, and to discuss potential new technologies for early lung cancer detection including AI, ethical and social considerations and legal aspects related to health data. Topics also include the Nelson trial and possible applications and limitations of the results.

12:30 BST / 13:30 CET

Welcome remarks

Professor Hans Hägglund, MD, National Cancer Coordinator, Swedish Association of Local Authorities and Regions and Confederation of Regional Cancer Centers. Chairman Vision Zero Cancer.

Jenni Nordborg, PhD, National Life Sciences Coordinator, The Office for Life Sciences, Government Offices of Sweden

Mattias Fredricson, Head of Unit responsible for national guidelines and screening, National Board of Health and Welfare

12:40 BST / 13:40 CET

Session 1 – Experiences of lung cancer screening studies in England

Presentations (15 min x 2) followed by Q & A and discussion (15 min)

Implementing Lung Cancer Screening: Manchester Lung Health Checks

Dr. Philip Crosbie, Clinical Senior Lecturer & Honorary Consultant in Respiratory Medicine, Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust

UK CT lung cancer screening trial (UKLS) and the trial at UCL looking at aspects of recruitment of the hard to reach

Professor David Baldwin, Consultant respiratory physician sub-specializing in lung cancer. Chair of the Clinical Expert Group for Lung Cancer, NHS England, and Clinical Director of the East Midlands Cancer Alliance

Session 2 – Potential new technologies for early lung cancer detection, including research on risk prediction for lung cancer and selection for screening

Brief presentations (10 min x 2) followed by Q & A (10 min)

Using biomarkers to improve early detection for lung cancer

Mattias Johansson, PhD, Scientist, Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), World Health Organization

Lung cancer screening and innovation: The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART)

John Kalafut, PhD - Chief Digital Research Scientist, GE Healthcare

Amied Shadman, Senior Program Manager, GE Healthcare

13:55 BST / 14:55 CET

Session 3 –The UK National Screening Committee views on a population screening programme for lung cancer

Presentation (15 min) followed by Q & A and discussion (15 min)

UKNSC and Lung Cancer Screening

Professor Anne Mackie, Director of Screening for Public Health England. Public Health England (PHE) provides support and advice to the NHS-led national screening programmes.

14:25 BST / 15:25 CET

Conclusion and Next Steps

14:30 BST / 15:30 CET

End of Meeting

Moderator: Ebba Hult, Head of Vision Zero Cancer

Date: Friday 25 September 2020
Time: 12:30-14:30 (UK) 13:30-15:30 (Sweden)
Place: Zoom Meeting
Contact: Ebba Hult, ebba.hult@hhs.se, +46 72 711 44 91

Link: <https://hhs-se.zoom.us/j/6266487000?pwd=eTVPcWtuMWJteFR5Vzk1R0JocGU5QT09>
Meeting ID: 626 648 7000
Passcode: 675913
Technical IT support: Available one hour before and during the web meeting
Jerker Mandell +46 766 322 965, zoomsupport@janedoe.se